Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;12(3):R120.
doi: 10.1186/ar3057. Epub 2010 Jun 22.

Immediate determination of ACPA and rheumatoid factor--a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay

Franziska Renger  1 , Holger Bang, Eugen Feist, Gert Fredenhagen, Alexander Natusch, Marina Backhaus, Gerd-R Burmester, Karl Egerer
Affiliations

Immediate determination of ACPA and rheumatoid factor--a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay

Franziska Renger et al. Arthritis Res Ther. 2010.

Abstract

Introduction: Autoantibodies against mutated and citrullinated vimentin (MCV) represent a novel diagnostic marker for rheumatoid arthritis (RA). Recently, an increased sensitivity for anti-MCV compared to autoantibodies against cyclic citrullinated peptides (anti-CCP2) was shown in cohorts of patients with early RA and established disease.The aim of this study was to develop and evaluate a point of care test (POCT) for detection of anti-MCV antibodies immediately at the first visit or at the bed side.

Methods: A lateral-flow immunoassay was developed for simultaneous detection of anti-MCV antibodies and rheumatoid factor (RF-IgG) and evaluated in a prospective setting. Analyses were performed from whole blood samples of patients with seropositive RA (n=108), seronegative RA as well as other rheumatic disorders (n=122), and healthy blood donors (n=200) and compared to detection via ELISA.

Results: Using the POCT, anti-MCV antibodies were detected in 54.6% and RF-IgG in 56.5% of patients with RA. Specificity was 99.1% for anti-MCV antibodies and 91.2% for RF-IgG. Compared to ELISA's results, POCT sensitivity was 69.3% for anti-MCV and 55.6% for RF-IgG, specificity was 99.7% and 97.2%, respectively.

Conclusions: This POCT for detection of anti-MCV antibodies and RF-IgG provides high specificity for the diagnosis of RA and is useful in clinical practice due to its simplicity and its reliable performance. This test can greatly improve a timely management of RA and may help in screening patients with suspected RA in non-specialized settings prompting early referrals.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Results.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:28–33. doi: 10.1093/rheumatology/39.1.28. - DOI - PubMed
    1. Eberhardt K, Larsson BM, Nived K, Lindqvist E. Work disability in rheumatoid arthritis--development over 15 years and evaluation of predictive factors over time. J Rheumatol. 2007;34:481–487. - PubMed
    1. Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007;56:2503–2511. doi: 10.1002/art.22817. - DOI - PubMed
    1. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther. 2006;8:R119. doi: 10.1186/ar2008. - DOI - PMC - PubMed
    1. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem. 2007;53:498–504. doi: 10.1373/clinchem.2006.078063. - DOI - PubMed

Publication types